Financials data is unavailable for this security.
View more
Year on year Turnstone Biologics Corp 's revenues fell -73.66% from 73.30m to 19.31m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 30.83m to a larger loss of 55.20m.
Gross margin | -- |
---|---|
Net profit margin | -- |
Operating margin | -- |
Return on assets | -98.52% |
---|---|
Return on equity | -- |
Return on investment | -127.31% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Turnstone Biologics Corp fell by 17.20m. Cash Flow from Financing totalled 77.05m or 399.08% of revenues. In addition the company used 66.15m for operations while cash used for investing totalled 28.09m.
Cash flow per share | -3.34 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.58 |
---|---|
Tangible book value per share | 2.58 |
More ▼
Balance sheet in USDView more
Current ratio | 4.38 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -241.67%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -- |